Franklin Resources’s VYNE Therapeutics VYNE Stock Holding History

Franklin Resources’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,341	Closed	-$14.4K	–	2399
2022 Q4	$14.4K	Hold	5,341	–	–	﹤0.01%	2290
2022 Q3	$21K	Hold	5,341	–	–	﹤0.01%	2254
2022 Q2	$37K	Sell	5,341 -2,581	-33%	-$21.7K	﹤0.01%	2274
2022 Q1	$93K	Hold	7,922	–	–	﹤0.01%	2308
2021 Q4	$145K	Sell	7,922 -98,813	-93%	-$2.12M	﹤0.01%	2290
2021 Q3	$2.67M	Buy	106,735 +1,131	+1%	+$43.9K	﹤0.01%	1380
2021 Q2	$6.67M	Buy	105,604 +11,756	+13%	+$931K	﹤0.01%	1077
2021 Q1	$11.6M	Hold	93,848	–	–	﹤0.01%	947
2020 Q4	$10.7M	Buy	93,848 +4	+0%	+$503	﹤0.01%	949
2020 Q3	$11.2M	Hold	93,844	–	–	0.01%	883
2020 Q2	$11.7M	Buy	+93,844	New	+$12.7M	0.01%	838
2018 Q2	–	Sell	-2,778	Closed	-$7.52M	–	1543
2018 Q1	$7.52M	Buy	+2,778	New	+$6.76M	﹤0.01%	977

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Franklin Resources's VYNE Position: Q1 2023 in Review

Franklin Resources sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 5,341 shares — an estimated $14.4K sold.

Franklin Resources first reported a position in VYNE in Q1 2018 and held it in 12 quarters. The position peaked at $11.7M in Q2 2020. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

Franklin Resources reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
Franklin Resources sold 5,341 VYNE Therapeutics shares in Q1 2023, an estimated $14.4K.
Franklin Resources first reported a position in VYNE Therapeutics in Q1 2018 and held it in 12 quarters.
Franklin Resources's VYNE Therapeutics position peaked at $11.7M in Q2 2020.
23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Franklin Resources's 13F filing for Q1 2023, filed 12 May 2023.